Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

August 22, 2026

Study Completion Date

August 22, 2026

Conditions
Breast Cancer
Interventions
DRUG

Iohexol 350 Mg/mL Injectable Solution

Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. Images will be acquired of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.

Trial Locations (1)

27599

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT05754749 - Comparison of CE-DBT and MRI in Patients With Known Breast Lesions | Biotech Hunter | Biotech Hunter